Welcome to our dedicated news page for Generation Bio Co. (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio Co. .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Generation Bio Co. 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Generation Bio Co. 's position in the market.
Rhea-AI Summary
Generation Bio Co. announced that six abstracts featuring preclinical data from its ctLNP and iqDNA platforms have been accepted for presentation at the ASGCT 27th Annual Meeting. The company will showcase its innovative work at the event, including an oral presentation on T-cell delivery with ctLNPs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.01%
Tags
-
Rhea-AI Summary
Generation Bio Co. (GBIO) CEO to participate in fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The event will be webcasted live and available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
-
News
Rhea-AI Summary
Generation Bio Co. (GBIO) reports progress in developing cell-targeted lipid nanoparticle delivery for sickle cell disease and beta-thalassemia, alongside advancements in immune-quiet DNA for hemophilia A. The company's cash balance of $264.4 million is expected to sustain operations till the second half of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
Rhea-AI Summary
Generation Bio Co. (GBIO) CEO to present at 2024 TD Cowen Health Care Conference, offering a live webcast for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.79%
Tags
-
Rhea-AI Summary
Generation Bio Co. (Nasdaq:GBIO) announced that Geoff McDonough, M.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, to discuss the company's genetic medicines for rare and prevalent diseases. A live webcast and replay will be available on the investor section of the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
-
Rhea-AI Summary
Generation Bio Co. (Nasdaq:GBIO) announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle (ctLNP) delivery system for wholly-owned programs in extrahepatic cell types. The company also intends to continue developing ctLNP for immune cells as part of its collaboration with Moderna and to develop its immune-quiet DNA (iqDNA) for its lead hemophilia A program and other programs. This strategic move will result in a 40% reduction of the workforce, but it is anticipated to extend the cash runway into the second half of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
Rhea-AI Summary
Generation Bio Co. (Nasdaq: GBIO) reported business highlights and third quarter 2023 financial results, including a cash balance of $291.0 million expected to fund operations into 2026. The company announced breakthroughs in genetic medicine with immune-quiet DNA (iqDNA) evading innate immune sensors in mice and non-human primates, and a proprietary cell-targeted lipid nanoparticle (ctLNP) delivery system showing highly selective T cell transduction in a humanized mouse model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.58%
Tags
-
Rhea-AI Summary
Generation Bio announces significant achievements in in vivo studies, demonstrating selective T cell targeting with its ctLNP platform and confirming stealth properties in non-human primates. The data show the potential for in vivo delivery to T cells and extrahepatic tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary
Generation Bio announces the development of immune-quiet DNA (iqDNA), a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.51%
Tags
Rhea-AI Summary
Generation Bio CEO to participate in fireside chat at Jefferies Cell & Genetic Medicine Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Generation Bio Co.
Nasdaq:GBIO
GBIO Rankings
GBIO Stock Data
189.46M
48.54M
14.47%
79.92%
1.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
CAMBRIDGE
About GBIO
generation bio is creating a revolutionary new class of genetic medicines that deliver durable, high levels of gene expression and have drug-like properties, including ability to titrate to effect and re-dose. our unique genewave technology allows us to overcome the limitations of other approaches by delivering larger genes, including more sophisticated regulatory elements, and avoiding the immunogenicity which limits both the number of patients who can be treated and the ability to re-dose them over time. we are a community of creative problem-solvers and independent thinkers. we are guided by strong personal integrity, humility, and the collaborative, learning mindset required to create solutions for patients and their families. to learn more about our efforts to usher in a new generation in medicine, please visit www.generationbio.com or our twitter feed, @lifetimegenetx.